Post di Dipartimento di Elettronica, Informazione e Bioingegneria - Politecnico di Milano

Fondazione Leonardo Med-Or presenta i primi tre anni di #attività da maggio 2021 ad oggi. Per scaricare il documento di #presentazione delle attività di Med-Or clicca qui 👇

🔥 Big News for MYLeukaemia Project! 🔥   🎉 We’re excited to share that MYLeukaemia Project has been selected as one of the Top 10 deeptech projects in the flagship BIP Acceleration Program by U.Porto Inovação!   💡 With support from CGD, Porto Business School, and UPTEC - Science and Technology Park of University of Porto, this program is the launchpad that takes us from lab research to real-world impact. It’s the bridge that turns breakthrough science into life-changing solutions—and it’s bringing us one step closer to the patients who need it most.   🚀 U.Porto Inovação & Porto Business School are playing a key role in turning Fundação para a Ciência e a Tecnologia (FCT) funded MYLeukaemia Project into more than just an exploratory project—it’s helping us build a startup that can change the way blood cancer is treated.   🩸 Stay tuned—this is just the beginning.   #MYLeukaemia #BIPAcceleration #UniversidadedoPorto #PortoBusinessSchool #BloodCancerSolutions

Cutting-edge News: 1 M€ fund-raising for TheraSonic with Gustave Roussy onboard !!!! This fund-raising is led by the European venture studio M2care, created at the initiative of Mérieux Développement, a specialist in healthtech, and associated with the project for a year prior to its creation. Gustave Roussy Transfert, a company dedicated to innovation and technology transfer, and a subsidiary of Gustave Roussy, Europe's leading cancer research center, is also investing in TheraSonic, to provide access to unique clinical expertise and ensure the earliest possible technological transition to the first patients. TheraSonic is a Medtech start-up whose ambition is to transform the treatment of neurological diseases by improving drug delivery to the brain. The startup will initially address brain metastases, which affect more than 30,000 new people every year in France. The treatment of brain cancers represents a market worth almost $4 billion in 2023, and could reach $7 billion by 2033, driven by the rising incidence of cancer and improved treatments for peripheral tumors. To meet this strong medical need, TheraSonic is developing a medical robot that enables the targeted delivery of ultrasound to the brain without surgery or anesthesia, during short therapeutic sessions. Combined with the intravenous injection of microbubbles, these focused ultrasounds induce a transient increase in the permeability of cerebral blood vessels, enabling drugs to reach their targets in the brain. TheraSonic was co-founded by Benoit Larrat and Anthony Novell, who have combined nearly 30 years of research into therapeutic ultrasound at the CEA (Atomic Energy Center) and CNRS (National Center for Scientific Research) respectively, and have invested over €3 million in the field since 2010. Their work has resulted in several patents and over 40 international scientific publications. Over the past 3 years, the company's project has benefited from the CEA's Magellan business start-up support program. The founding team is complemented by the M2care venture studio, which provides human support, with the involvement of 6 people and a financial investment of over 900 k€. In autumn 2023, TheraSonic has been selected by the Paris-Saclay Cancer Cluster to support its development. As such, TheraSonic benefits from privileged access to the cancer ecosystem (training courses, network of experts, offices, clinical trials, etc.). Benoit Larrat, President and co-founder of TheraSonic, comments: "This first financing round provides us with the resources we need to rapidly implement the first clinical trial of our technology, with the aim of bringing its benefits to patients as quickly as possible. In this context, the choice of the venture studio model is an appropriate one, as it contributes to the company's development by providing expertise complementary to scientific and medical skills, and enables us to focus our initial recruitment on the technology." (more in comments...)

L'obiettivo di InnoNP è superare gli ostacoli nella traslazione delle nanostrutture al letto del paziente. Nanoparticelle magnetiche ingegnerizzate con un coating di nuova concezione, che permette loro di sfuggire alla cattura da parte del sistema immunitario, costituiscono sia un nuovo agente di contrasto, meno tossico degli attuali, sia una piattaforma che facilita lo sviluppo di nuove nanomedicine. 𝖨𝗇𝗇𝗈𝖭𝖯: 𝖨𝗇𝗇𝗈𝖼𝖾𝗇𝗍 𝖭𝖺𝗇𝗈𝖯𝖺𝗋𝗍𝗂𝖼𝗅𝖾𝗌 è tra i vincitori di Seed4Innovation 2023, il programma di innovazione di Fondazione UNIMI e Università degli Studi di Milano. Scopri i progetti premiati: 👉 https://lnkd.in/dJuTXDS5 UNIMI Innova Consiglio Nazionale delle Ricerche Università degli Studi di Pavia #Seed4Innovation #S4I #innovazione #nanoparticelle Operating Partner: Deloitte, BUGNION SpA, CA Group   Research Partner: Ospedale Galeazzi - Sant'Ambrogio, FONDAZIONE IRCCS ISTITUTO NEUROLOGICO CARLO BESTA, IEO Istituto Europeo di Oncologia, Centro Cardiologico Monzino, Ospedale Policlinico di Milano   Corporate Partner & Investor: Extend | the National Technology Transfer Biotech Hub & Farming Future - CDP Venture Capital SGR, Indaco Venture Partners, STMicroelectronics Italia, Bio4Dreams, Fondazione Golinelli, Indicon Società Benefit (SB)   Media Partner: Tecniche Nuove Healthcare

Proud and honored to be reelected as Board Member of Atlanpole Biotherapies, and to join the management office for the next 3 years ! A Big thank you to our association members for their votes, and the board for their trust. Atlanpole Biotherapies is one of the largest bio cluster in France, located in the western part of the country. It gathers three regions, and includes innovative companies operating in the health tech segment (biotech, medtech, Health AI, CDMO, CRO, Bioproduction..). Here are few figures (France Biotech Health Tech Panorama 2023) on how Atlanpole Biotherapies members impact the health tech sector in France: - 44% of national total revenues - 18% of national R&D expenses - 26% of national FTE French, European and international pharma & biotech companies and investors, come and see how our association can support your portfolio and operation expansion !

La ricerca italiana deve diventare un asset di sviluppo del Paese. E in tal senso deve essere sempre più chiaro che la ricerca accademica non è un costo ma un investimento per il Paese. Parole del cardiochirurgo GIULIO POMPILIO, direttore scientifico del Centro Cardiologico Monzino e responsabile scientifico del progetto #PerfeTTO, che mette in rete gli uffici di #trasferimentotecnologico di 54 enti di eccellenza italiani, tra istituti di ricovero e cura a carattere scientifico #irccs e università. 📌 Per fare trasferimento tecnologico servono competenze, capacità di visione, risorse: umane, tecnologiche, finanziarie. 📌 E il professor Pompilio spiega nell'intervista che si legge su INNLIFES che con PerfeTTO si vuole proprio iniettare risorse negli uffici di trasferimento tecnologico per dotarli di professionalità e know-how per poter contribuire fattivamente a generare valore dalla ricerca accademica #lifescience #scienzedellavita #innovazione 🔎 https://lnkd.in/dbVR-P-Q IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST Srl ENTE OSPEDALIERO SAVERIO DE BELLIS ISTITUTO DI RICOVERO E CURA A CARATTERE SCIENTIFICO Azienda Ospedaliera Universitaria Meyer - IRCCS IRCCS Centro di Riferimento Oncologico IEO Istituto Europeo di Oncologia Ospedale Pediatrico Bambino Gesù Università degli studi di Palermo Università degli Studi di Messina Università Campus Bio-Medico di Roma ... (sono 54 gli istituti scientifici e gli atenei del network)

Ieri, in occasione della Giornata della #Ricerca di ICS Maugeri SpA Società Benefit, è stato proiettato anche un breve video di interviste ai ricercatori del nostro #IRCCS, al quale ho avuto il piacere di partecipare. Si tratta di un tentativo di raccontare il lavoro della ricerca al mondo esterno che partiva da 3 domande solo apparentemente semplici: 1) come mai hai scelto di fare ricerca 2) cosa vuol dire fare ricerca 3) di cosa si occupano le tue ricerche Il risultato è molto piacevole e potrebbe essere di interesse per tutti. Sono solo un paio di minuti che vi consiglio di dedicare per comprendere meglio questo lavoro.

Proud and honored to be reelected as Board Member of Atlanpole Biotherapies, and to join the management office for the next 3 years ! A Big thank you to our association members for their votes, and the board for their trust. Atlanpole Biotherapies is one of the largest bio cluster in France, located in the western part of the country. It gathers three regions, and includes innovative companies operating in the health tech segment (biotech, medtech, Health AI, CDMO, CRO, Bioproduction..). Here are few figures (France Biotech Health Tech Panorama 2023) on how Atlanpole Biotherapies members impact the health tech sector in France: - 44% of national total revenues - 18% of national R&D expenses - 26% of national FTE French, European and international pharma & biotech companies and investors, come and see how our association can support your portfolio and operation expansion !

BOOSTER FOR LIFE SCIENCE - TRL ADVANCEMENT è l’iniziativa promossa dal Cluster Scienze della Vita del Friuli Venezia Giulia con il sostegno della Regione Autonoma Friuli Venezia Giulia per finanziare con 10.040.000 euro progetti di #ricerca industriale e sviluppo sperimentale nel settore delle #ScienzedellaVita che potranno ottenere singolarmente un contributo da 200.000 a 500.000 euro. L’intervento ha lo scopo di sostenere progetti di ricerca finalizzati all’innalzamento del livello di maturità tecnologica (TRL) di prodotti e servizi in fase di sviluppo, supportando sia la validazione di idee sia lo sviluppo di tecnologie innovative, e di consentire l’avvicinamento delle soluzioni all’ingresso a mercato. L’avviso è aperto a una vasta platea di attori del campo imprenditoriale ed accademico: PMI e grandi imprese, startup innovative, spin-off, università e organismi di ricerca. Possono presentare domanda di contributo soggetti provenienti da tutto il territorio nazionale che si impegnano a costituire un’unità operativa in Friuli Venezia Giulia entro la data di avvio del progetto. Info: https://lnkd.in/d_juQBZp #ClusterALISEI #lifesciences

Why healthtech marketing is complicated, and specified from marketing? It is like "standard" marketing, right? These are typical questions, I meet regularly, and even though that they are quite valid, there are things we need to mention to see the full picture. If we really simplify it, marketing as a sales support engine, is a very complex set of rules and tools, which could be best friend and the worst time, money and energy consuming enemy of any companies. Majority of healthtech entrepreuners does not have the competence and experience in business fields, therefore marketing seems to be a necessary burden. At the beginning, then later thoughtful planning can bring expert to the team, who can tame the wild horse of commercialization, but unfortunately in many cases it remains in a cage with the huge sign „proceed with caution”. This is the first, and the most important environmental circumstance, which requires a special approach when we are talking both lecturing and using marketing, in health tech companies. The second and more time consuming, which even requires stronger internal competence is to select the efficient set of tools and channels, serving certain business needs and goals. This process starts with solid planning, lot of internal iterations and then a continous measurement and finetuning. Of course the journey starts with the proper education, and this field has a very special role in the accelerator programmes, I have the opportunity to manage or support. On March 13th, I will run a Healthtech Marketing training for the 9 great startups (https://lnkd.in/djMD5mqF), selected for EIT Health InnoStars and Roche challenge based programme. During the training I will focus on the following topics: 💡 Personas and messaging 💡 Strategy vs Plan 💡 Essentials of KPIs 💡 Funnels 💡 Healthcare Marketing 💡 Digital Marketing 💡 Analog Marketing 💡 Next Steps in the journey Based on my experience and last years' feedbacks, this is a great starting package for early stage startups to launch their journey and start to utilize the potential values of a carefully planned and executed marketing strategy.